Citigroup Inc. restated their buy rating on shares of Shire PLC (LON:SHP) in a research note issued to investors on Tuesday.
Other equities research analysts have also issued research reports about the company. J P Morgan Chase & Co reaffirmed an overweight rating and set a GBX 6,300 ($78.62) price target on shares of Shire PLC in a research note on Monday, December 5th. Deutsche Bank AG reaffirmed a buy rating and set a GBX 6,200 ($77.37) price target on shares of Shire PLC in a research note on Wednesday, November 2nd. Bank of America Corporation reaffirmed a buy rating and set a GBX 6,970 ($86.98) price target on shares of Shire PLC in a research note on Thursday, November 3rd. Jefferies Group LLC reaffirmed a buy rating and set a GBX 6,600 ($82.37) price target on shares of Shire PLC in a research note on Thursday, January 5th. Finally, Liberum Capital reaffirmed a buy rating and set a GBX 5,500 ($68.64) price target on shares of Shire PLC in a research note on Thursday, December 22nd. Fifteen analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The company has an average rating of Buy and an average target price of GBX 6,034.57 ($75.31).
Shire PLC (LON:SHP) traded up 0.82% during midday trading on Tuesday, reaching GBX 4402.00. The company had a trading volume of 1,692,069 shares. The company has a 50-day moving average price of GBX 4,576.12 and a 200-day moving average price of GBX 4,831.88. The stock’s market capitalization is GBX 39.63 billion. Shire PLC has a one year low of GBX 2,707.19 and a one year high of GBX 5,377.00.
In related news, insider Olivier Bohuon purchased 141 shares of the business’s stock in a transaction that occurred on Friday, December 16th. The shares were bought at an average price of GBX 4,528 ($56.51) per share, for a total transaction of £6,384.48 ($7,967.65).
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.